Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Wednesday, March 13, 2019 at 8:40am ET.

The presentation will be webcast and may be accessed at the Events & Presentations section of the Companys website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Primes product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Primes product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com or follow us on: LinkedInTwitter and Facebook.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Media and Investor Contact
Martin Forrest
VP, Investor
Relations & Corporate Communications
Five Prime Therapeutics,
Inc.
415-365-5625
[email protected]